Semaglutide shortage eased

Semaglutide works by copying a gut hormone that tells the brain “you’re full” and slows how fast food leaves the stomach, so people often eat less without white-knuckling hunger. Tirzepatide adds a second signal on top of that, which is one reason these drugs have reshaped obesity treatment so quickly. (fda.gov) That success created a strange problem: demand outran supply for years, and semaglutide injections were added to the Food and Drug Administration shortage system during the boom in Ozempic and Wegovy prescribing. The Food and Drug Administration now says the national shortage is resolved, meaning supply at the country level meets current and projected demand. (fda.gov) National supply is not the same thing as every shelf being full. Pharmacy Times reported that local pharmacies can still see patchy availability even after the Food and Drug Administration removed semaglutide injections from the shortage list, so patients may still run into delays depending on dose and location. (pharmacytimes.com) The shortage label also mattered because it opened a lane for compounders, which are pharmacies and outsourcing facilities that make customized versions when a commercial drug is hard to get. The Food and Drug Administration said on April 1, 2026 that semaglutide and tirzepatide are not currently on the shortage list and reminded compounders that copies of approved drugs have to meet narrow legal conditions. (fda.gov) Now the medical story is shifting from “can patients find the drug” to “what happens when they stay on it.” A real-world study presented through the European Association for the Study of Obesity tracked 116 users of these medicines and found many were eating so much less that protein, fiber, calcium, iron, magnesium, potassium, choline, and vitamins A, C, D, and E could fall short. (news-medical.net) That does not mean the drugs are failing. It means appetite suppression can work so well that a smaller plate stops being a balanced plate, the same way cutting a grocery bill in half can accidentally cut out basics instead of just snacks. (news-medical.net) A separate six-month study of 200 adults offers a more reassuring piece of the picture. Patients on semaglutide or tirzepatide lost weight and body fat with only minimal loss of lean mass, and the group had been coached on resistance training and protein intake by an obesity specialist. (news-medical.net) Lean mass is the body’s working hardware: muscle, organs, connective tissue, and everything that is not stored fat. Earlier worries around rapid weight loss focused on losing too much of that hardware, so the new result suggests the drug is only part of the outcome and the food and exercise plan around it may decide whether weight loss is mostly fat or partly muscle. (sciencedirect.com) The next twist is genetics. A Nature study of 27,885 people found a variant in the glucagon-like peptide-1 receptor gene linked to stronger weight-loss response, with about 0.76 kilograms of extra weight loss per copy of the effect allele, and it also found genetic signals tied to side effects. (nature.com) That helps explain why one person can lose more than 20 percent of body weight on these drugs while another loses less than 5 percent, even when both are taking the same class of medicine. Euronews reported the researchers think this could eventually help doctors match patients to treatment more precisely instead of using today’s trial-and-error approach. (euronews.com) So the shortage story is easing, but the semaglutide story is getting more detailed. The new picture is a drug that is easier to source nationally, still uneven locally, powerful enough to create nutrition gaps if eating drops too far, and variable enough that genes may help explain who gets the best results and who gets the roughest ride. (fda.gov) (pharmacytimes.com) (news-medical.net) (nature.com)